Methylene Blue
Methylene Blue (Methylthioninium Chloride)
A synthetic dye and the world's first synthetic drug — now studied as a mitochondrial electron carrier with cognitive and neuroprotective properties.
Methylene Blue is FDA-approved (Provayblue) for the treatment of acquired methemoglobinemia. This page discusses the compound in broader research contexts beyond its approved indication. Use outside the approved indication, including for cognitive or longevity purposes, is not FDA-sanctioned and should be discussed with a qualified healthcare provider.
What it is
Methylene blue was first synthesized in 1876 and was the world's first synthetic pharmaceutical drug. It is FDA-approved for one indication: methemoglobinemia (a blood disorder where hemoglobin cannot carry oxygen). Everything else discussed here is off-label research.
Its mechanism in longevity and nootropic contexts is distinct from most compounds: methylene blue acts as an alternative electron carrier in the mitochondrial electron transport chain. When the ETC is impaired (as occurs with aging and in neurodegenerative disease), methylene blue can shuttle electrons directly, partially bypassing the dysfunctional complexes and restoring ATP production.
Importantly, methylene blue follows a hormetic dose-response curve — low doses are beneficial and high doses can cause oxidative harm. Most research suggests the therapeutic window is at low doses (0.5–4mg/kg).
What research shows
- Restores mitochondrial function by acting as an alternative electron carrier — bypasses Complex I–III dysfunction
- Cognitive enhancement in rodent and early human studies
- TauRx/LMTX Phase 2/3 trials studied a derivative for Alzheimer's disease — mixed results but signals of effect
- Neuroprotective in models of Parkinson's, Alzheimer's, and traumatic brain injury
- Anti-aging effects in human skin fibroblasts — reduced oxidative stress markers
- Antidepressant properties in some animal models
What remains unknown
- Optimal dosing in humans for cognitive and longevity benefits — hormetic curve is not well-defined
- Long-term safety profile with chronic low-dose use
- Serotonin syndrome risk — methylene blue is a MAO inhibitor and dangerous with serotonergic drugs
- Whether cognitive benefits in animal models translate robustly to humans
Administration basics
Common use cases
Cognitive enhancement, mitochondrial support, neuroprotection, longevity protocols.
Half-life
~5–6 hours.
Administration
Oral solution or capsules. Pharmaceutical-grade (USP) sourcing is critical — industrial grade contains impurities. Turns urine blue at typical doses.
Research Protocols & Common Usage
Doses used in research
- Research studies have used 0.5–4mg/kg for various indications
- Community low-dose cognitive protocols commonly report 1–10mg/day orally
- Hormetic dosing is widely discussed — low doses may be beneficial while high doses may be pro-oxidant
Administration routes studied
Typical protocol duration
Community protocols range from acute use to daily ongoing low-dose. Cycling is commonly recommended.
Common stacking protocols
- Methylene Blue + Red light therapy — combined based on research into synergistic mitochondrial activation
- Methylene Blue + NAD+ precursors — combined in mitochondrial optimization protocols
Contraindications & combinations to avoid
- SSRIs, SNRIs, MAOIs, and all serotonergic medications — SERIOUS INTERACTION: Methylene Blue inhibits MAO-A and can cause serotonin syndrome; this is a potentially life-threatening combination
- G6PD deficiency — contraindicated; can cause hemolytic anemia
- Psychedelics — potential adverse interaction
- Note: Methylene Blue causes blue-green discoloration of urine; this is expected and not harmful
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with Methylene Blue and what to avoid.
Track your Methylene Blue protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the Methylene Blue page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.